ArticleCureus2024
Bleeding Phenotype of Glanzmann Thrombasthenia (GT) and Treatment Outcomes in Over One Hundred Patients: A Two-Center Experience in North Pakistan.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiological and clinical characteristics of children and young adults with Glanzmann's thrombasthenia in upper Egypt: a multicenter cross-sectional study.Annals of hematology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlanzmann thrombasthenia (GT) is a rare disease with an autosomal recessive inheritance pattern. This disorder is not so uncommonly encountered in routine clinical practice and laboratory settings in Pakistan let alone in the rest of the world. To describe the bleeding phenotype of GT and treatment outcomes in over one hundred patients in north Pakistan. MATERIALS AND
methodsThis descriptive, cross-sectional, retrospective study was conducted on patients from 2011 to 2023 using a convenience sampling technique. A total of 103 patients of all ages and both genders diagnosed as having inherited GT were included in the study.
resultsThe median age of the study population was 1.1 years, with an interquartile range (IQR) of 0.8-2. Out of the total, 55 (53%) patients were males and 48 (47%) patients were females. Ninety-eight percent of patients were diagnosed using light transmission aggregometry, and only two (2%) patients were diagnosed by immunophenotyping. Due to the high incidence of interfamily marriages, 86 (84%) patients were born to consanguineous marriages. Thirty-nine (38%) patients had an episode of major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria. Epistaxis in 73 (71%) patients, skin bruising in 63 (61%), and gum bleeding in 57 (55%) were the most common bleeding symptoms. Thirty-two (31%) required the use of r-VIIa for major bleeding and five (5%) patients underwent fully matched allogeneic HSCT (hematopoietic stem cell transplant). Graft versus host disease-free relapse-free survival (GRFS) was 80%.
conclusionGT is still an underrecognized and underdiagnosed disorder, particularly in resource-limited settings where the estimated incidence seems to be much higher than reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.